

ATHEROGENICS INC
Form 8-K
July 24, 2003

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 24, 2003

ATHEROGENICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Georgia
(State or other jurisdiction
of incorporation)

0-31261
(Commission
File Number)

58-2108232
(I.R.S. Employer
Identification Number)

8995 Westside Parkway
Alpharetta, GA 30004
(Address of principal executive offices)

Registrant's telephone number, including area code **(678) 336-2500**

TABLE OF CONTENTS

SIGNATURES

EXHIBIT INDEX

EX-99.1 PRESS RELEASE DATED 7/24/03

Table of Contents

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

Exhibits.

See Exhibit Index attached to this current report on Form 8-K.

Item 9. Regulation FD Disclosure (furnished pursuant to Item 12, Results of Operations and Financial Condition.)

On July 24, 2003, AtheroGenics, Inc. issued a press release to report the company's financial results for the quarter ended June 30, 2003. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ATHEROGENICS, INC

Date: July 24, 2003

/s/ MARK P. COLONNESE

Mark P. Colonnese
Senior Vice President of Finance and Administration and Chief
Financial Officer

Table of Contents

EXHIBIT INDEX

The following exhibit is furnished as part of this current report on Form 8-K.

Exhibit No.	Description
99.1	Press Release dated July 24, 2003